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Abstract
Background: India has announced a goal of universal access to quality tuberculosis (TB) diagnosis and treatment. A number
of novel diagnostics could help meet this important goal. The rollout of one such diagnostic, Xpert MTB/RIF (Xpert) is being
considered, but if Xpert is used mainly for people with HIV or high risk of multidrug-resistant TB (MDR-TB) in the public
sector, population-level impact may be limited.
Methods and Findings: We developed a model of TB transmission, care-seeking behavior, and diagnostic/treatment
practices in India and explored the impact of six different rollout strategies. Providing Xpert to 40% of public-sector patients
with HIV or prior TB treatment (similar to current national strategy) reduced TB incidence by 0.2% (95% uncertainty range
[UR]: 21.4%, 1.7%) and MDR-TB incidence by 2.4% (95% UR: 25.2%, 9.1%) relative to existing practice but required 2,500
additional MDR-TB treatments and 60 four-module GeneXpert systems at maximum capacity. Further including 20% of
unselected symptomatic individuals in the public sector required 700 systems and reduced incidence by 2.1% (95% UR:
0.5%, 3.9%); a similar approach involving qualified private providers (providers who have received at least some training in
allopathic or non-allopathic medicine) reduced incidence by 6.0% (95% UR: 3.9%, 7.9%) with similar resource outlay, but
only if high treatment success was assured. Engaging 20% of all private-sector providers (qualified and informal [providers
with no formal medical training]) had the greatest impact (14.1% reduction, 95% UR: 10.6%, 16.9%), but required .2,200
systems and reliable treatment referral. Improving referrals from informal providers for smear-based diagnosis in the public
sector (without Xpert rollout) had substantially greater impact (6.3% reduction) than Xpert scale-up within the public sector.
These findings are subject to substantial uncertainty regarding private-sector treatment patterns, patient care-seeking
behavior, symptoms, and infectiousness over time; these uncertainties should be addressed by future research.
Conclusions: The impact of new diagnostics for TB control in India depends on implementation within the complex,
fragmented health-care system. Transformative strategies will require private/informal-sector engagement, adequate
referral systems, improved treatment quality, and substantial resources.
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Despite being a largely curable disease, tuberculosis (TB) causes
8.7 million new cases and 1.4 million deaths per year, over 25% of
which—including cases caused by ‘‘totally drug-resistant’’
strains—occur in India [1,2]. Over the last 15 y, the Revised
National Tuberculosis Control Programme (RNTCP) has made
great strides in improving TB control efforts in the public sector.
However, TB incidence in the country continues to be stubbornly
high [1]. In part, TB control efforts in India have been hampered
by inadequate and inconsistent diagnostic and treatment practices
[1–6].
India has a complex health-care system with a wide range of
different informal, private, and public providers. In India, the
large private sector [7] diagnoses nearly half of all TB cases [8,9].
This sector consists of individuals who provide medical care
outside of the public system and can be broadly divided into
informal providers with no formal medical training (who generally
provide very low levels of care [4,10,11]) and those who have
received at least some training in allopathic or non-allopathic (e.g.,
Ayurveda, Unani, homeopathic) medicine [8,12]. Patients select
providers based on a number of factors, including convenience,
cost, and trust; relative to private care, public-sector care may be
free but is often less trusted and less convenient [13].
Furthermore, while the RNTCP may be widely recognized, most
people with underlying TB initially seek care for cough, not
‘‘presumed TB.’’ They therefore generally first visit nearby
informal providers, including chemists, and later more qualified
practitioners [12], often seeing several providers [14] before
diagnosis. Public-sector diagnosis is often seen as a last resort for
those with no money, no other options, or symptoms sufficiently
persistent and severe to suggest TB as a likely diagnosis.
Ultimately, over half of patients are diagnosed in the public
sector [8,9]. The full diagnostic process from symptom onset to
initiation of treatment can take months, during which individuals
remain infectious [14]. This fragmented system of care-seeking
has spurred efforts to encourage private providers to adhere to
Standards for TB Care in India and refer individuals with
suspected TB to the public sector [15,16].
Currently, however, the public sector relies on sputum smear
microscopy that misses half of all cases [17], and while culture is
available on a limited basis, culture results rarely influence clinical
decision-making [18]. The private sector often uses diagnostic tests
with even worse performance [6]. Serological, antibody-based tests
were popular until their ban in 2012 on the basis of high cost (often
$30 or more) and poor accuracy [19]. Subsequently, concern has
been raised about the growing use of interferon-gamma release
assays (IGRAs) for active TB diagnosis [5,6,20]. Both antibody
and IGRA tests are discouraged by the current Standards for TB
Care in India [15]. Testing for multidrug-resistant TB (MDR-TB)
is rarely undertaken in either the public or private sector [1,21].
Xpert MTB/RIF (Xpert, Cepheid Inc, Sunnyvale, CA, USA) is
a novel molecular test for active TB that uses semi-automated
PCR to amplify mycobacterial DNA [22,23]. It has a higher
sensitivity than sputum smear microscopy, and, in addition,
through the use of specific primers it can detect mutations
associated with rifampin resistance. Whereas TB culture can take
months to provide these results, Xpert can be performed in 90 min
[22]. A demonstration study—including testing in India—found
that Xpert could be performed with high sensitivity in decentral-
ized settings [24], a feasibility study showed that obstacles such as
high temperature and error rates could be overcome in India [25],
and prior modeling analyses in southern Africa have suggested
that Xpert rollout could have important epidemiological impact
[26].
Currently, the RNTCP is mainly implementing Xpert not for
broad high-sensitivity diagnosis of TB but rather primarily as a
rapid drug susceptibility testing (DST) method in adults and
children with HIV or high risk of MDR-TB [15,16,25,27]. While
there is some effort to expand access to the private sector via
public–private mix models [27], the central goal is currently to
improve DST capacity in the public sector. The comparative
population-level impact of various potential rollout strategies in the
public versus private sectors remains unclear, especially as this
impact depends not just on test accuracy, but also on the
appropriate placement of the test—and linkage to appropriate
treatment—early in the diagnostic pathway. To better understand
the potential epidemiological impact and resource requirements
for strategies in which Xpert is scaled up across different health-
care sectors, we constructed a transmission model of TB that
incorporates provider and patient behavioral patterns within the
Indian health-care system.
Methods
Model Structure: TB Diagnosis, Treatment, and Care-
Seeking
We developed a compartmental model that uses ordinary
differential equations to describe the current TB epidemic and
health-care system in India (Figures 1 and S1). Regarding TB
natural history, this model expands on other published models of
TB by incorporating a ‘‘before diagnosis-seeking stage’’ (partially
infectious but not seeking diagnosis for any symptoms [28,29]) and
a diagnosis-seeking phase (symptoms sufficiently severe to prompt
care-seeking). During diagnosis-seeking, TB is categorized as
either highly infectious (diagnosable by sputum smear) or less
infectious (not diagnosable by sputum smear). Rates of seeking
diagnosis are based on estimates from the literature [12], with each
diagnostic attempt occurring in the informal sector (providers with
no formal medical training), the qualified private sector (providers
who have received at least some training in allopathic or non-
allopathic medicine), or the public sector (medically trained
providers in the national health-care system) (Table 1). The
probability of successful diagnosis and treatment differs according
to sector, and both the speed of diagnosis and probability of loss to
follow-up before treatment differ across tests. After unsuccessful
diagnostic attempts, patients continue seeking diagnosis, with the
sector of the subsequent diagnostic attempt conditional on the
preceding attempt. Thus, individuals tend to progress from seeking
care initially in the informal sector, then the qualified private
sector, and finally the public sector as repeated diagnostic attempts
fail. Since the diagnosis of pediatric and extrapulmonary TB is
generally distinct from that of adult pulmonary TB, we consider
only the latter. Two authors independently checked and ran the
code to minimize errors. Model parameters are shown in Table 2.
A detailed description of the model compartments and equations is
set out in Tables S1 and S2 and Texts S1 and S2.
MDR-TB, TB Treatment, and HIV
Since Xpert can detect resistance to rifampin [21,30], we
modeled infection with drug-susceptible and rifampin-resistant TB
(as a proxy for MDR-TB) as separate strains, with rifampin
resistance propagating through both inadequate treatment (po-
tentially different across sectors) and transmission of resistant
strains. In the absence of Xpert, we assumed that all newly
diagnosed individuals receive first-line treatment lasting 6 mo,
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rates) across the public and qualified private sectors. In sensitivity
analysis, we considered lower treatment success in the private
sector [3,31–33]. All cases with a history of TB treatment are
initially placed on an 8-mo retreatment regimen. We assumed that
half of individuals with MDR-TB fail these therapies and remain
infectious [34]. A small proportion of cases with MDR-TB
treatment failure are started on appropriate second-line therapy
(20 mo). HIV infection accounts for a small minority (4.2%) of
individuals with active TB in India [1]. Nevertheless, we included
people living with HIV as a parallel population with higher TB
risk and mortality.
Model Calibration
We initiated our model at steady state, reflecting trends in India
prior to 2005. Taking all other parameters as fixed, we fitted the
Figure 1. Model schematic. Diagram of the compartments in the model. Not shown, but present in the model, are parallel structures by (a) HIV
status and (b) MDR-TB status.
doi:10.1371/journal.pmed.1001674.g001
Table 1. Movement between health-care providers.
Care-Seeking Behavior Informal Qualified Private Public
Initial provider approached 69% 31% 0%
Subsequent provider visited
Previous provider informal 48% 49% 3%
Previous provider qualified private 3% 36% 61%
Previous provider public 0% 0% 100%
Where TB infected individuals initially go to seek diagnosis and the location of subsequent visits [12].
doi:10.1371/journal.pmed.1001674.t001
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Parameter Value Sensitivity Range Source
Transmissibility, highly infectious TB 12.0 y
21 —
a Fitted value
Adult mortality rate 0.02 y
21 0.015–0.025 [8,45]
HIV adult mortality rate 0.05 y
21 0.025–0.1 [28,29,46]
TB mortality rate, HIV-negative individuals,
highly infectious TB
0.22 y
21 0.3–0.5 [12,47]
Relative mortality in highly infectious versus less
infectious TB, HIV-negative individuals
b
0.29 0.20–0.35 [21,30,47]
TB mortality rate, HIV-positive individuals 1y
21 0.75–1.25 [38,48–50]
Proportion of cases that are highly infectious
HIV-negative individuals 0.65 0.5–0.8
c [17,49]
HIV-positive individuals 0.35 0.26–0.44
c [1,17,51]
Proportion of infections that progress rapidly to active TB
HIV-negative individuals 0.14 0.05–0.2
c,d [1,52]
HIV-positive individuals 0.4 0.2–0.8
c [1,53]
Relative transmission capability of less infectious TB 0.22 0.17–0.28 [8,54]
Lost to follow-up between initial presentation
and treatment initiation
— [35,36]
Xpert, smear 0.15 0.05–0.25
Other diagnostics 0.25 0.13–0.5
c
Proportion of patients with drug-susceptible
TB who develop MDR-TB during treatment
0.008 0.006–0.01 [1,55]
Endogenous activation of latent TB, per year [56]
HIV-negative individuals 0.001 0.0007–0.0012
c,d
HIV-positive individuals 0.023 0.017–0.029
c,d
Protective factor from previous infection,
HIV-negative individuals only
0.6 0.2–0.8 [52]
Time infectious before symptoms 4.1 mo 0–6 mo Fitted value
Time from symptoms to seek diagnosis 4.8 mo 1–6 mo [12]
Initial sector visited by TB suspect [12]
Informal sector 0.69 0.61–0.77
Qualified private sector 0.31 0.23–0.39
Public sector 0.00 0–0.2
Time to seek second opinion 1.9 mo 1.5–2.4 mo [12]
Site of next diagnostic attempt
(informal/qualified private/public)
—
e [12]
Current diagnostic attempt: informal sector 0.48/0.49/0.03 —
Current diagnostic attempt: qualified private sector 0.03/0.36/0.61 —
Current diagnostic attempt: public sector 0/0/1 —
Probability of being diagnosed correctly,
primary infection, highly infectious TB
f
Informal sector (without Xpert) 0 Unchanged Model assumption
Qualified private sector (without Xpert) 0.38 0.27–0.45 Fitted value
Public sector (without Xpert) 0.98 0.85–1 Model assumption
Xpert 0.98 0.85–1 [22]
Probability of being diagnosed correctly,
primary infection, less infectious TB
f
Informal sector (without Xpert) 0 Unchanged Model assumption
Qualified private sector (without Xpert) 0.2 0.1–0.5 Model assumption
Public sector (without Xpert) 0.2 0.1–0.5 Model assumption
Xpert 0.73 0.6–0.8 [22]
Probability of treatment success [1,34]
First-line regimen/retreatment (not MDR-TB) 0.95 0.9–1.0
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(number of transmitted infections per person-year), calibrated to
the WHO-estimated overall TB incidence [1]; the duration of
infectiousness before symptom onset, calibrated to the WHO-
estimated duration of TB disease (prevalence/incidence ratio) [1];
and the probability of TB diagnosis in the qualified private sector,
calibrated to estimates of the case notification proportion,
assuming that non-notified cases are diagnosed and treated in
the private sector [8].
We fit the model to the data shown in Table 3 in a model run to
steady state using a quasi-Newton method [35]. After achieving
steady state, we instituted a 2%/y decline in per capita TB
incidence, to reflect the pre-Xpert (2005–2011) epidemiological
situation in India [1].
Impact of Xpert
Where available, we assumed Xpert improved diagnosis and
treatment as follows (numbers in parentheses denote sensitivity
analysis ranges): increased sensitivity for less infectious (smear-
negative) TB from 0%–20% (depending on health-care sector) to
73% (60%–80%); increased sensitivity to highly infectious TB
from 0%–98% to a uniform 98% (80%–100%); reduced
probability of loss to follow-up before treatment initiation for
smear-negative TB (25%) to that of smear-positive TB (15%, with
Table 2. Cont.
Parameter Value Sensitivity Range Source
First-line regimen/retreatment (MDR-TB) 0.53 0.4–0.6
Second-line regimen (MDR-TB) 0.70 0.6–0.8
Proportion of MDR-TB cases successfully diagnosed as
MDR-TB within 2 wk and put on second-line therapy
[22]
Without Xpert 0 Unchanged
With Xpert 0.94 0.8–1
Delay between diagnosis and treatment initiation 0.5 mo 0–1 mo Model assumption
Self-cure rate, highly infectious TB (HIV-negative
individuals only)
0.1 0.01–0.1
c [47]
Self-cure rate, less infectious TB
(HIV-negative individuals only)
0.27 0.1–0.3
c [47]
aSensitivity analysis conducted by varying the transmission rate such that annual incidence changed by 625%. In the multiway analysis, parameter combinations that
resulted in more than a 25% change in baseline incidence were discarded.
b‘‘Highly infectious’’ means ‘‘diagnosable by smear.’’ Individuals with highly infectious TB are assumed to be less infectious until seeking diagnosis. ‘‘Less infectious’’
means ‘‘not diagnosable by smear.’’
cIn multiway sensitivity analyses, some parameter values were made to correlate with each other so they either both increase or both decrease from their base value: (1)
the proportion of infections that are highly infectious in those HIV2 and those HIV+; (2) the proportion of individuals that progress rapidly in those HIV2 and HIV+;( 3 )
losses to follow-up between culture, Xpert, and smear; (4) endogenous activation of TB for those HIV2 and HIV+; (5) the self-cure rate for highly infectious and less
infectious TB.
dTransmission rate varied so that incidence remained constant.
eWhere current diagnostic attempt is made in the informal sector, sensitivity range for next visit being to the qualified private sector is 0.25–0.75. The movement to the
public sector is unchanged at 0.03, and remaining in the informal sector is the balancing figure (022–0.72). Where current diagnostic attempt is made in the qualified
private sector, sensitivity range for next visit being to the public sector is 0.4–0.8. The movement to the informal sector is unchanged at 0.03, and remaining in the
private sector is the balancing figure (0.17–0.57).
fIndividuals with a history of TB treatment had an increased probability of diagnosis of half the difference between one and the probability of diagnosis for first-time
infections (model assumption).
doi:10.1371/journal.pmed.1001674.t002
Table 3. Model calibration.
Data point Reported Value Adjusted Value Fitted Value Source
Prevalence (per 100,000) 249 293 293 [1]
Annual incidence (per 100,000) 181 213 213 [1]
TB mortality (per 100,000) 24 29 29 [1]
Proportion of TB infections in HIV+ individuals 0.042 0.042 0.042 [1]
Proportion MDR-TB in all infections 0.021 0.021 0.021 [1]
Proportion of diagnoses made in qualified private sector 0.4 0.4 0.4 [8]
The reported values represent the estimated burden of TB in India. The adjusted values reflect the adult-only rates for pulmonary TB (the reported values represent all
individuals and include pulmonary and extrapulmonary TB, whereas our model is an adult-only model of pulmonary TB). The fitted value represents the value we
obtained in our model following our calibration exercise. Adjusted values were calculated using the fact that individuals aged 15 y and under represent 2% of notified
cases and 30% of the population and that 85% of TB cases are pulmonary TB [1].
doi:10.1371/journal.pmed.1001674.t003
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with similar turnaround time to smear [1,2,36]; and increased
sensitivity for rifampin resistance from 0% to 94% (80%–100%)
After fitting the starting model as above, we modeled six
different Xpert rollout scenarios, comparing them to a baseline
scenario of no Xpert access (Table 4). Each rollout scenario was
run for 5 y. For each scenario, we selected 20% as an a priori
coverage level that might be feasible at the country level, yet could
have measureable population-level impact. The baseline scenario
assumed no improved diagnostic testing. Scenario 1 (‘‘public
sector, HIV/high MDR-TB risk only’’) assumed that 40% of
individuals with TB symptoms presenting to the public sector who
were either HIV-positive or had a history of TB treatment would
be tested with Xpert [1,3–5,21,27]. Scenario 2 (‘‘broad public
sector’’) assumed Xpert access for 40% of individuals with HIV/
high MDR-TB risk as above, plus 20% of all other individuals with
TB symptoms (presumed TB) seeking diagnosis in the public sector
(e.g., in upgraded peripheral microscopy centers). Scenario 3
(‘‘qualified private sector’’) assumed Xpert access for 40% of
individuals with HIV/high MDR-TB risk in the public sector, as
in scenario 1, plus 20% of all symptomatic individuals seeking care
from qualified private practitioners (e.g., through private lab
networks). Scenario 4 (‘‘public plus qualified private sectors’’)
assumed access for the populations in both scenarios 2 and 3.
Scenario 5 (‘‘broad cross-sector access’’) was designed to show the
potential effect of Xpert distributed across all sectors, assuming
Xpert access for 20% of all diagnostic encounters, including
incentives for informal providers to refer patients to either the
public sector (e.g., via public–private mix) or qualified private
providers. Scenario 6 (‘‘increased referral’’) modeled the indepen-
dent effect of incentivizing referrals from the informal sector to the
public sector, without the added sensitivity of Xpert. Here, we
assumed that 20% of individuals with TB who sought diagnosis in
the informal sector were subsequently referred to the public sector
for their next diagnostic attempt (up from 3% in the base case),
with diagnosis made in the public sector by sputum smear
microscopy.
To calculate the minimum number of GeneXpert systems
required to conduct testing, we assumed that each system
contained four modules, ran at a capacity of 16 tests per day,
and operated 300 d per year (i.e., 4,800 tests per year). To
conservatively estimate the total number of Xpert tests run, we
assumed that 10% of all Xpert tests were conducted on individuals
with underlying TB (i.e., 90% of tests were run on people without
TB) in scenarios 2–4 [17,24], increasing to 20% in scenario 1 and
declining to 5% in scenario 5. Using these estimates, we also
constructed analyses in which 100 GeneXpert systems were rolled
out at maximum capacity, but across different sectors. As of
December 31, 2013, the equivalent of 135 four-module GeneX-
pert systems had been procured in India under concessionary
pricing [37].
Sensitivity Analysis
Some data suggest that TB drug prescriptions are suboptimal
[3,4,7] and treatment outcomes in the private sector may be
inferior compared with the public sector [3,31–33]. Therefore, we
conducted an alternative analysis where we assumed lower-quality
treatment in the private sector [3,4,11,21,32,38]. In this analysis,
individuals diagnosed and treated by qualified private practitioners
had a 5-fold increase in the probability of developing MDR-TB
during treatment (4% per treatment, versus 0.8% in the public
sector) and a reduced probability of cure (75% versus 95%).
The broad rollout of Xpert in the public sector (scenario 2) may
lead to behavioral changes in both patients and private providers
that lead to increased care-seeking in, or referral to, the public
sector, especially for MDR-TB, which is expensive to treat in the
private sector. We therefore conducted a sensitivity analysis where
the rollout of Xpert was accompanied by a 50% increase in
seeking care within the public sector after a private-sector
encounter.
We also conducted one-way sensitivity analyses using the
deterministic model described above. We varied each model
parameter in turn to the upper and lower bounds of the ranges
given in Table 2 to assess the impact on model outcomes.
Uncertainty Analysis
In addition to the sensitivity analyses above, to obtain measures
of uncertainty that also included the impact of the random nature
of both the disease and health-care behavior processes, we built a
stochastic version of the model. We used a Gillespie stochastic
simulation algorithm to incorporate stochasticity for each transi-
tion in our model [39]. The stochastic model used a population of
10 million individuals, and we conducted 10,000 runs of the model
for each scenario. In each run, we simultaneously varied all
parameter values using Latin hypercube sampling (i.e., probabi-
listic sensitivity analysis). We used a beta distribution with an alpha
Table 4. Scenario overview.
Scenario
Public Sector (High
Risk for MDR-TB)
Public Sector (Low
Risk for MDR-TB)
Qualified Private
Sector Informal Sector
Baseline Sputum smear
microscopy, no Xpert
Sputum smear
microscopy, no Xpert
Existing mix of tests in
private sector, no Xpert
Existing mix of tests in
private sector, no Xpert
1. Public sector, HIV/high
MDR-TB risk only
Baseline + Xpert for 40% Baseline Baseline Baseline
2. Broad public sector Baseline + Xpert for 40% Baseline + Xpert for 20% Baseline Baseline
3. Qualified private sector Baseline + Xpert for 40% Baseline Baseline + Xpert for 20% Baseline
4. Public plus qualified
private sectors
Baseline + Xpert for 40% Baseline + Xpert for 20% Baseline + Xpert for 20% Baseline
5. Broad cross-sector access Baseline + Xpert for 40% Baseline + Xpert for 20% Baseline + Xpert for 20% Baseline + Xpert for 20%
6. Increased referral Baseline Baseline Baseline Baseline
The table shows the diagnostic algorithm used for each scenario to diagnose TB among individuals with respiratory symptoms in whom a diagnosis of TB is being
considered. We do not consider active screening in this model.
doi:10.1371/journal.pmed.1001674.t004
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each parameter. This approach therefore incorporated both
parameter uncertainty and underlying stochastic uncertainty.
Where we expected sets of parameters to be closely correlated,
we varied their values in the same direction and magnitude
within any simulation. We linked parameter values for TB
natural history elements (e.g., proportion of rapid progression) for
people with and without HIV, losses to follow-up across all
diagnostic tests, and spontaneous resolution rates regardless of
TB smear status, using correlation coefficients of 1.0 for
transparency. All 95% uncertainty ranges (URs) reported in the
manuscript reflect the 2.5th and 97.5th quantiles of the final
distribution of outcomes under this procedure. To explore the
independent influence of each parameter on the impact of Xpert
after adjusting for the effects of all other parameters in the model,
we calculated partial rank correlation coefficients (PRCCs) for the
correlation between each parameter’s value and key model
outcomes [7,40].
Software
All analyses were conducted in R version 2.12 [41].
Results
Model Fit
The baseline model reflected estimates of the TB epidemic in
India, with a TB incidence of 213 per 100,000 individuals per year
among adults, prevalence of 293 per 100,000 (i.e., mean duration
of disease as estimated by prevalence/incidence ratio=1.38 y),
TB mortality of 29 per 100,000 individuals per year, and MDR-
TB prevalence of 2.1% among all incident active TB (Table 3).
These values corresponded to a TB infection rate of 12.0 infections
per highly infectious person-year, a total pre-diagnostic period
(including time during which symptoms may be unnoticeably mild)
of 9.0 mo, and probability of diagnosis in the qualified private
sector of 38% per diagnostic attempt. The mean time from onset
of infectiousness to first visiting an informal provider was 8.9 mo,
increasing to 11.5 mo to visit to a qualified private provider and
14.8 mo to visit the public sector (among those who ever presented
to the public sector).
Impact of Xpert Scale-Up Scenarios
In the baseline scenario (no new diagnostic intervention), TB
incidence fell from 213 to 192 per 100,000 individuals per year
over 5 y (i.e., continued 2% annual decline), whereas MDR-TB
prevalence remained stable. Introducing Xpert into the public
sector for 40% of HIV-positive individuals and individuals at high
risk of MDR-TB (scenario 1) had a negligible epidemiological
impact, with the uncertainty ranges for the effect on each of the
epidemiological measures (incidence, prevalence, mortality, and
MDR-TB incidence) including zero (Figure 2). We estimated that
TB incidence in this scenario would fall slightly (192 per 100,000
individuals per year, a 0.2% decline relative to baseline, 95% UR:
21.4%, 1.7%); however, it would enable 14,000 additional true-
positive MDR-TB diagnoses over a 5-y time period. If these
individuals were appropriately treated, the impact on MDR-TB
(from 4.4 to 4.2 per 100,000 individuals per year, a 2.4% decline,
95% UR: 25.2%, 9.1%) and TB mortality (0.9% decline, 95%
UR: 21.6%, 3.5%) was more substantial (Table 5). Assuming that
Xpert could be performed at near-maximum capacity (16 tests per
machine-day, 300 d/y), such an implementation at the country
level would require continuous use of 60 four-module GeneXpert
systems in centralized laboratories—about half of the number of
modules procured country-wide through 2013. Using Xpert on
smear-positive specimens only would lower this requirement to 11
systems while preserving two-thirds of the impact on MDR-TB
incidence (1.7% decline), but sacrificing most of the impact on TB
mortality (0.02% reduction).
If Xpert was made available to 20% of symptomatic individuals
seeking care in the public sector (in addition to 40% of individuals
with HIV/high MDR-TB risk as above) (scenario 2), incidence fell
to 189 per 100,000 individuals per year (2.1% decline relative to
baseline, 95% UR: 0.5%, 3.9%) over 5 y, with correspondingly
larger relative effects on TB mortality (25 per 100,000 individuals
per year, 3.3% decline, 95% UR: 1.0%, 6.1%) and MDR-TB
incidence (4.1 per 100,000 individuals per year, 3.6% decline,
95% UR: 22.9%, 9.3%). However, such an implementation
would require 3.2 million annual tests, or 700 continuously
running GeneXpert systems, approximately one per district (India
has 680 districts), and over five times as many systems as had been
procured via concessionary pricing through 2013.
Figure 2. Impact of Xpert after 5 y. Percentage reduction in annual incidence, prevalence, mortality, and MDR-TB incidence from an Xpert rollout
after 5 y in six different scenarios. The final set represents an alternative scenario where there is an increase in referrals from the informal sector to the
public sector to 20% with no Xpert rollout.
doi:10.1371/journal.pmed.1001674.g002
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3) had greater impact on incidence (6.0% reduction, 95% UR:
3.9%, 7.9%), and with similar resource requirements (700
systems), assuming treatment success equivalent to that in the
public sector. Correspondingly, broad access to Xpert in both
public and private sectors (scenario 4) produced only a slight
incremental impact compared to access in the qualified private
sector only, with overlapping uncertainty ranges between the two
scenarios in each of the epidemiological measures (Figure 2),
reflecting the fact that nearly all individuals diagnosed in the
public sector were previously seen by qualified private providers.
In analyses of rolling out 100 maximum-capacity GeneXpert
systems across different sectors, Xpert access in the qualified
private sector had more than twice the impact on overall incidence
of access in the public sector, whereas targeting high-risk
individuals had 5–10 times more impact on MDR-TB than non-
targeted strategies (Figure 3). Assuming poorer treatment out-
comes in the private sector caused the relative benefit of private-
sector Xpert access to disappear (Figure 4).
Where we considered incorporating access to all providers—
assuming referral from the informal sector to other providers for
appropriate treatment (scenario 5)—such broad-based access
dramatically increased the impact on incidence (14.1% reduction,
95% UR: 10.6%, 16.9%), but at substantial additional resource
requirement (2,200 Xpert systems required). As an alternative to
Xpert rollout, simply increasing access to public-sector smear
diagnosis (scenario 6) had a large effect: if 20% of symptomatic
individuals seeking care at informal providers were simply referred
to the public sector on their next attempt, incidence was reduced
by 6.3% without any use of Xpert at all (Figure 2).
Sensitivity Analyses
In both one-way analyses (Figure 5) and sensitivity analyses that
adjusted for the simultaneous effects of all other parameters
(Figure S2), the effect of Xpert for people with HIV or previous
TB treatment (scenario 1) on MDR-TB incidence was most
sensitive to the success of second-line therapy for patients with
MDR-TB. If second-line therapy cured only 60% of MDR-TB
cases, Xpert would reduce MDR-TB incidence by only 1.2% after
Table 5. Effect of Xpert rollout on annual TB incidence and mortality after 5 y compared to baseline scenario with no Xpert.
Scenario Cases Averted
a Deaths Averted
a
MDR-TB Cases
Averted
a,b
Additional MDR-TB
Diagnoses (610
3/y,
All India
a,c)
Total Number of Xpert
Tests Conducted
(610
3/y, All India
a,c,d)
Minimum Number of
Xpert systems
Required (All
India
a,c,e)
1. Public sector,
HIV/high MDR-TB
risk only
0.2% [21.4, 1.7]
(0.3 per 100,000)
0.9% [21.6, 3.5]
(0.2 per 100,000)
2.4% [25.2, 9.1]
(0.1 per 100,000)
2.5 [1.4, 4.4] 300 [250, 420] 60 [50, 90]
2. Broad public
sector
2.1% [0.5, 3.9]
(4.0 per 100,000)
3.3% [1.0, 6.1]
(0.9 per 100,000)
3.6% [22.9, 9.3]
(0.2 per 100,000)
4.7 [3.0, 6.6] 3,200 [2,400, 4,000] 700 [490, 840]
3. Qualified private
sector
6.0% [3.9, 7.9]
(11.5 per 100,000)
8.1% [5.6, 10.5]
(2.1 per 100,000)
6.8% [1.0, 12.4]
(0.3 per 100,000)
5.9 [3.9, 7.7] 3,500 [2,600, 3,900] 700 [530, 810]
4. Public plus
qualified private
sectors
7.2% [4.9, 9.5]
(13.9 per 100,000)
9.6% [7.0, 12.3]
(2.5 per 100,000)
7.5% [5.7, 10.6]
(0.3 per 100,000)
7.2 [5.0, 9.1] 5,100 [3,700, 5,800] 1,100 [770, 1,220]
5. Broad cross-
sector access
14.1% [10.6, 16.9]
(27.2 per 100,000)
18.1% [15.0, 20.8]
(4.7 per 100,000)
12.1% [7.9, 18.0]
(0.5 per 100,000)
7.7 [5.2, 9.2] 10,800 [8,000, 12,100] 2,200 [1,670, 2,510]
6. Increased
referral
6.3% [4.0, 9.0]
(12.2 per 100,000)
7.6% [5.0, 10.1]
(2.0 per 100,000)
3.2% [20.6, 7.5]
(0.1 per 100,000)
—— —
a95% uncertainty ranges provided in square brackets.
bAssuming second-line treatment is available for those diagnosed with MDR-TB.
cEstimated population of India by 2019 is 1.3 billion.
dAssumes 20% of Xpert tests are performed on individuals with TB for scenario 1, 10% for scenarios 2–4, and 5% for scenario 5.
eAssumes four runs per day per module and each machine has four modules and operates 300 d/y.
doi:10.1371/journal.pmed.1001674.t005
Figure 3. Impact of 100 Xpert systems rolled out in different
sectors after 5 y. Reduction in total annual incidence and MDR-TB
incidence per 100,000 individuals from a rollout of 100 Xpert machines.
The scenarios are as described in the Methods. Rollout of 100 Xpert
machines in the private sector has substantially greater impact than a
similar rollout in the public sector, but only if high treatment success
can be assured. If treatment is poor, use of Xpert machines in the
private sector has no epidemiological benefit.
doi:10.1371/journal.pmed.1001674.g003
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impact of Xpert in the public sector (scenario 2) was most sensitive
to the baseline probability of diagnosis in the public sector:
increasing the diagnosis probability for less infectious (smear-
negative) TB from 10% to 50% changed the impact of Xpert on
TB incidence from 3.3% to 1.4% (Figure 5D). The transmission
fitness of MDR-TB did not substantively affect the relative impact
of Xpert on MDR-TB incidence (PRCC 20.01), nor did wide
variation in the structure of care-seeking attempts after the initial
visit (e.g., 25%–75% probability of seeking care in the qualified
sector after an informal sector attempt, PRCC 0.35) (Figure S2).
Including an additional active disease compartment resulted in
identical estimates of the impact of Xpert across all scenarios,
reflecting the near-equilibrium conditions of the baseline scenario
(Text S3). If broad public-sector rollout increased the probability
of seeking care in the public sector (after a private-sector
encounter) by 50%, incidence fell by an estimated 4.4%, greater
than the 2.1% estimated with no behavior change, but still lower
than the impact of rollout to the qualified private sector (Figure 6).
Discussion
Xpert is more sensitive than other diagnostics in current
widespread use, but its cost is substantial, and the Indian
health-care system is fragmented and heavily privatized. These
circumstances pose challenges for the design of an optimal
implementation strategy. Currently, the RNTCP is mainly
implementing Xpert as a rapid DST method among high-risk
cases seeking care in the public sector; our model suggests that the
impact of this strategy on the overall TB epidemic in India will be
limited. By contrast, scale-up of Xpert access to include qualified
providers (e.g., through private lab networks), or improving
referrals from informal to public providers with no Xpert at all,
could have a substantial impact (6% reduction in incidence after
5 y, or over 30,000 lives saved per year, three times more than a
public-sector Xpert rollout of similar scope). In addition, the only
rollout scenarios that produced reductions in MDR-TB incidence
in which the 95% uncertainty range excluded zero were those that
provided Xpert access to the private sector (and assumed high-
quality treatment within that sector).
The impact of Xpert for TB control in India therefore depends
not only on test accuracy, but also on the implementation strategy,
reliable linkages to high-quality treatment, and commitment of
resources. These findings are relevant to policy in India, and more
broadly in implementing the National Strategic Plan (2012–2017)
[16] for TB made by the RNTCP that considers the most
appropriate way to scale up Xpert or better alternatives that may
emerge in the future.
A key consideration of any Xpert implementation strategy will
be the costs associated with each approach. Costs will vary
depending on a large number of factors including machine
placement (decentralized versus centralized network of laborato-
ries), transportation and maintenance costs, future pricing
schemes, development of next-generation diagnostic tests, costs
of providing free MDR-TB treatment in the public sector, and
costs to patients (both direct and indirect). Thus, we focus here on
the number of GeneXpert systems required to achieve various
rollout strategies, as a proxy for required resources. In generating
these estimates, we assumed that each module would perform four
tests a day, but this number may be optimistic, as module failure,
cartridge stock-outs, laboratory logistics (e.g., specimen transport),
and insufficient numbers of samples or staff could all reduce the
daily capacity of an Xpert module. A recent pilot study in India
processed two samples per module per day [25]; if this capacity is
applied to all implemented modules, our estimates of the number
of four-module GeneXpert systems required double. Even using
our optimistic assumptions, however, the number of systems
required even for our broad public-sector or qualified private-
sector scenarios (700 four-module systems, or over US$10 million
in equipment prices alone, with cartridges costing over three times
more) are unlikely to be realized in the short term without
dramatic increases in funding. This funding, however, need not
come entirely from the public sector; given the potential for Xpert
to have even greater epidemiological impact if deployed in the
private sector, innovative mechanisms should be pursued to
replace existing resource outlays in the private sector (e.g., using
Xpert rather than non-approved tests for active TB) and to speed
patient access (e.g., using referral systems or specimen transport
networks) to high-quality TB diagnosis throughout India, without
saddling patients with extra out-of-pocket costs. Such systems are
Figure 4. Impact of differential treatment failure between
public and private providers. The qualified private sector represents
a wide range of operations, many of which are believed to provide poor
levels of treatment. To explore the potential impact of a rollout of Xpert
access for 20% of patients seeking care in the qualified private sector
where the treatment provided in the qualified private sector is poorer
than that provided in the public sector, we ran three sensitivity
analyses. Sensitivity A represents the main analysis with no difference
between the private and public sectors. In Sensitivity B, patients put on
treatment in the private sector have twice the probability of developing
MDR-TB as those put on treatment in the public sector, and lower levels
of treatment success. In Sensitivity C, patients put on treatment in the
private sector have five times the probability of developing MDR-TB as
those put on treatment in the public sector, and lower levels of
treatment success.
doi:10.1371/journal.pmed.1001674.g004
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engagement of a diverse spectrum of stakeholders in the Indian
health-care system.
To provide perspective on resource requirements, through
2013, the country had acquired the equivalent of 135 four-
module GeneXpert systems via concessionary pricing [37], less
than one-fifth that required for our 20% scale-up scenarios.
Treatment of the 43,800 additional patients found to have MDR-
TB over 5 y would require even greater resource outlay. Thus,
for Xpert to have substantial population-level impact in India, the
private sector must be engaged, but a dramatic increase in
resource allocation is also essential. These resources need not
come only from the public sector; engaging private lab networks
may make Xpert more affordable in the private sector as well
[1,4,8,10–12,20,42]. One model for such engagement is the
Initiative for Promoting Affordable and Quality TB Tests
(http://www.ipaqt.org/), through which nearly 50 Xpert
systems have been installed in private labs across India that offer
WHO-endorsed tests at more affordable prices in the private
sector [20,42]. Furthermore, to the extent that private-sector
resources can be diverted from inappropriate diagnostic tests
(e.g., serology and IGRAs for active TB) to high-quality tests of
similar price (e.g., Xpert), implementation of Xpert in India has
the potential to be both less costly and more effective than the
current standard of care in TB diagnosis.
A previous model of Xpert rollout in southern Africa estimated a
6% reduction in annual incidence after 10 y [26], similar to our
scenario 3, with 20% access in the private sector. Our ‘‘idealized
access’’ scenario (scenario 5) projects greater impact on incidence
(14% reduction after 5 y), reflecting lower levels of HIV co-infection,
but would be so resource-intensive as to be currently unrealistic.
Another model of hypothetical TB diagnostics in a generic Southeast
Asian context [43] found that sensitivity and point-of-care amena-
bility—as characteristics of such hypothetical assays—represented
tradeoffs in terms of impact; by contrast, the present model is fit
specifically to the Indian epidemiological and health-care system,
Figure 5. One-way analysis of parameter sensitivity. The parameters were changed in turn to the maximum (red) and minimum (green) values
from Table 2. The effect of Xpert after 5 y on MDR-TB incidence and overall incidence in scenarios 1 ([A] and [B]) and 2 ([C] and [D]) was recorded for
each new value. The five parameters to which the model is most sensitive are shown in the diagrams. In both cases, the most important parameters
in one-way sensitivity analysis reflected aspects of the existing health-care system in India, not characteristics of the diagnostic assay itself.
doi:10.1371/journal.pmed.1001674.g005
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(Xpert) being actively discussed at the policy level in India, and
includes country-specific data on patient pathways to care. We show
that these aspects of the health-care system, patient and provider
behavior, and implementation strategy are at least as important—if
not more so—than specific assay characteristics when evaluating the
potential impact of TB diagnostic tests in India.
This model represents a first attempt to explore the interactions
between rollout of a novel TB diagnostic test and a complex
underlying health-care system, highlighting how patient and
provider practices may affect TB incidence in the population.
For Xpert or any other diagnostic test to reach maximum potential
in India, engaging the private sector and assuring high-quality care
will be critical; scenarios that included only the public sector or
assumed poor treatment success proved inadequate for TB
control. Facilitating referrals from the informal sector to the
public sector (e.g., through innovative incentive schemes, public–
private interface agencies [PPIAs], or social franchising) [44] can
also have a dramatic impact, rivaling that of any Xpert rollout.
The RNTCP’s National Strategic Plan for TB in India includes a
PPIA component to improve quality of care in the private sector
and increase referrals to the public sector [16]; two urban pilot
PPIA projects are underway [44]. Although India’s TB diagnostic
pathways are in many ways unique, our quantitative estimates
reflect that unique system, and our key findings (e.g., importance
and resource intensity of engaging the private sector) may
generalize to other countries—especially those in Southeast Asia
and the Western Pacific—with large private sectors and persis-
tently high TB incidence despite relatively low levels of HIV and
drug-resistant TB on a population level.
As with any mathematical representation, our model has certain
limitations. It does not account for difficulties in implementation,
inaccessibility or high costs of high-quality MDR-TB treatment, and
nuanced HIV dynamics. Model results also reflect the quality of
underlying data, and there remain key uncertainties regarding
symptoms and infectiousness among TB patients. In addition, TB
prevalence among people seeking care (with and without Xpert
availability) remains poorly understood. Individuals with more
severe symptoms may present at the public sector earlier, which
might increase the impact of public-sector Xpert rollout on
mortality. We conducted multiple sensitivity analyses on all
parameters and found our results to be largely robust to
parameter misspecification, although our uncertainty ranges are
wide, reflecting uncertainty in the underlying data.
Understanding care-seeking pathways is essential to under-
standing the impact of novel diagnostics in the real world. As data
on care-seeking behavior in the private sector are sparse, our
estimates are based on a single cross-sectional study of patients
who ultimately presented to the public sector. While we varied
these estimates using wide uncertainty ranges, this work highlights
important gaps in our knowledge, including the need for better
data on the amount of time spent before seeking diagnosis, patient
care-seeking pathways upon seeking diagnosis, and the quality of
TB care in the private sector.
In conclusion, Xpert (and by extension, other novel diagnostics
with similar or improved characteristics) could substantially reduce
the burden of TB disease due to poor diagnosis in India; however,
this impact depends not only on the accuracy of the test, but also
on the behavior of both patients and providers, their level of access
to new tools, and quality TB treatment following diagnosis. As
such, any Xpert rollout strategy must also consider the complex
health-care infrastructure into which the test is being rolled out.
To achieve maximum impact of novel diagnostics, India should
engage the private sector, improve quality of care across all sectors,
and dramatically increase resources.
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Background. Tuberculosis—a contagious bacterial disease
that usually infects the lungs—is a global public health
problem. Each year, about 8.7 million people develop active
tuberculosis and about 1.4 million people die from the
disease. Mycobacterium tuberculosis, the bacterium that
causes tuberculosis, is spread in airborne droplets when
people with active disease cough or sneeze. The character-
istic symptoms of tuberculosis are a persistent cough, fever,
weight loss, and night sweats. Diagnostic tests for tubercu-
losis include sputum smear microscopy (microscopic analysis
of mucus coughed up from the lungs), the growth of M.
tuberculosis from sputum samples, and new molecular tests
(for example, the automated Xpert MTB/RIF test) that rapidly
and accurately detect M. tuberculosis in patient samples and
determine its resistance to certain antibiotics. Tuberculosis
can be cured by taking several antibiotics daily for at least six
months, although the recent emergence of multidrug-
resistant (MDR) tuberculosis is making the disease increas-
ingly hard to treat.
Why Was This Study Done? About 25% of all tuberculosis
cases occur in India. Most people in India with underlying
tuberculosis initially seek care for cough from the private
health-care sector, which comprises informal providers with
no formal medical training and providers with some training
in mainstream or alternative medicine. Private providers
rarely investigate for tuberculosis, and patients often move
between providers, with long diagnostic delays. The public
sector ultimately diagnoses and treats more than half of
tuberculosis cases. However, the public sector relies on
sputum smear microscopy, which misses half of cases, and
the full diagnostic process from symptom onset to treatment
initiation can take several months, during which time
individuals remain infectious. Could the rollout of molecular
diagnostic tests improve tuberculosis control in India? The
Indian Revised National Tuberculosis Control Programme
(RNTCP) is currently introducing the Xpert MTB/RIF test
(Xpert) as a rapid method for drug susceptibility testing in
the public sector in people at high risk of MDR tuberculosis,
but is this the most effective rollout strategy? Here, the
researchers use a mathematical transmission model to
investigate the likely effects of the rollout of Xpert in India
using different implementation strategies.
What Did the Researchers Do and Find? The researchers
explored the impact of several rollout strategies on the
incidence of tuberculosis (the number of new cases of
tuberculosis in the population per year) by developing a
mathematical model of tuberculosis transmission, care-
seeking behavior, and diagnostic/treatment practices in
India. Compared to a baseline scenario of no improved
diagnostic testing, provision of Xpert to 40% of public-sector
patients at high risk of MDR tuberculosis (scenario 1, the
current national strategy) reduced the incidence of tubercu-
losis by 0.2% and the incidence of MDR tuberculosis by 2.4%.
Implementation of this strategy required 2,500 additional
courses of MDR tuberculosis treatment and the continuous
use of 60 Xpert machines, about half the machines procured
in India during 2013. A scenario that added access to Xpert
for 20% of all individuals with tuberculosis symptoms
seeking diagnosis in the public sector and 20% of individuals
seeking care from qualified private practitioners to scenario 1
reduced the incidence of tuberculosis by 14.1% compared to
the baseline scenario but required more than 2,200 Xpert
machines and reliable treatment referral. Notably, a scenario
that encouraged informal providers to refer suspected
tuberculosis cases to the public sector for smear-based
diagnosis (no Xpert rollout) had a greater impact on the
incidence of tuberculosis than Xpert scale-up within the
public sector.
What Do These Findings Mean? These findings are
subject to considerable uncertainty because of the assump-
tions made in the transmission model about private-sector
treatment patterns, patient care-seeking behavior, and
infectiousness, and the quality of the data fed into the
model. Nevertheless, these findings suggest that the rollout
of Xpert (or other new diagnostic methods with similar
characteristics) could substantially reduce the burden of
tuberculosis due to poor diagnosis in India. Importantly,
these findings highlight how the impact of Xpert rollout
relies not only on the accuracy of the test but also on the
behavior of patients and providers, the level of access to new
tools, and the availability of treatment following diagnosis.
Thus, to ensure that new diagnostic methods have the
maximum impact on tuberculosis in India, it is necessary to
engage the whole private health-care sector and to provide
adequate referral systems, improved treatment quality, and
increased resources across all health-care sectors.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001674.
N The World Health Organization (WHO) provides informa-
tion (in several languages) on all aspects of tuberculosis,
including general information on tuberculosis diagnostics
and specific information on the roll out of the Xpert MTB/
RIF test; further information about WHO’s endorsement of
Xpert MTB/RIF is included in a Strategic and Technical
Advisory Group for Tuberculosis report; the Global
Tuberculosis Report 2013 provides information about
tuberculosis around the world, including in India
N The Stop TB Partnership is working towards tuberculosis
elimination and provides patient stories about tuberculosis
(in English and Spanish); the Tuberculosis Vaccine Initiative
(a not-for-profit organization) also provides personal
stories about tuberculosis
N The US Centers for Disease Control and Prevention has
information about tuberculosis and its diagnosis (in English
and Spanish)
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N TBC India provides information about tuberculosis control
in India, including information on the RNTCP
N The Initiative for Promoting Affordable and Quality TB
Tests promotes WHO-endorsed TB tests in India
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
Impact of Xpert Implementation Strategy on TB in India
PLOS Medicine | www.plosmedicine.org 14 July 2014 | Volume 11 | Issue 7 | e1001674